|
23 Jul 2019 |
Personalized gene-edited immune cell therapy for patients with solid cancers: New data establishes approach for verifying patient-specific cancer mutation targets
|
|
23 Jul 2019 |
Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa
|
|
23 Jul 2019 |
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
|
|
23 Jul 2019 |
Achillion’s ACH-5228 Achieves Positive Results in Phase 1 Multiple Ascending Dose Study in Healthy Volunteers
|
|
23 Jul 2019 |
Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors
|
|
23 Jul 2019 |
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
|
|
23 Jul 2019 |
Resolve Therapeutics Announces Completion of Enrollment for Phase 2a Study of RSLV-132 for the Treatment of Lupus
|
|
23 Jul 2019 |
Vertex Submits New Drug Application to the U.S. FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis
|
|
23 Jul 2019 |
IMFINZI® (durvalumab) US Label Updated With Overall Survival Data in Unresectable, Stage III Non-small Cell Lung Cancer
|
|
23 Jul 2019 |
Gilead Presents Proof-of-Concept Data for GS-6207, a First-in-Class Capsid Inhibitor, in People Living With HIV
|
|
23 Jul 2019 |
ViiV Healthcare presents positive 96-week data from phase III study of investigational fostemsavir in heavily treatment-experienced patients with HIV at IAS 2019
|
|
23 Jul 2019 |
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin as Adjunctive Treatment for Patients with Schizophrenia
|
|
22 Jul 2019 |
Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center
|
|
22 Jul 2019 |
Investigational Subcutaneous Formulation of Vedolizumab Meets Primary Endpoint in Achieving Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn's Disease
|
|
22 Jul 2019 |
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis
|
|
21 Jul 2019 |
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
|
|
21 Jul 2019 |
PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke
|
|
21 Jul 2019 |
Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
|
|
21 Jul 2019 |
FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
|
|
21 Jul 2019 |
Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX® (daratumumab)
|
